Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis

Inclusion Criteria: * Male patients \> 18yrs * Osteoporosis prophylaxis/therapy with * vitamin D 800 - 1200 mg per day, * calcium 800 - 1000 mg per day, * Fosamax 70 once a week. * Standardised physiotherapy exercise programme. * No proliferative bone disease. * No history of calcium oxalate stones. * No use of aromatase inhibitors. * No use of 5-alpha reductase inhibitors. Nebido group: * No contraindications to use of Nebido (known prostate or breast carcinoma or suspicion thereof, no past or present history of liver tumours); * No known hypersensitivity to testosterone or excipients of Nebido Exclusion Criteria: * Androgen dependent carcinoma of the prostate or male mammary gland, past or present history of liver tumours, hypersensitivity towards the active pharmaceutical ingredient or other ingredients.